Viewing nowNeuromantine Tablet 20mg (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Tablet · Prescription medication
JongkunDang Co., Ltd.

MFDS item code 202500939 · Approved 2025.04.21 · Insurance code 643309810
Treatment of moderate to severe Alzheimer's disease
This medicine is used to treat moderate to severe Alzheimer's disease. It helps improve the decline in memory and cognitive function of the patient, contributing to the maintenance of daily living abilities.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver is able to regularly check that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed regularly. This medicine is administered orally once daily and should be taken at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1-7): Administer 5mg daily for 7 days. Week 2 (days 8-14): Administer 10mg daily for 7 days. Week 3 (days 15-21): Administer 15mg daily for 7 days. From week 4 onward: Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment No dose adjustment is required for patients with mild renal impairment (creatinine clearance: 50-80 mL/min). For patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated for at least 7 days after administration, the dose may be increased to 20mg daily according to the standard dose-escalation method. For patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medicine should not be used by patients who have allergic reactions to its ingredients or have severe liver or kidney dysfunction. Caution should be taken when used in patients with epilepsy or those with a history of seizures and when used in combination with certain medications, as the risk of side effects may increase. Additionally, it should be given with caution to patients with conditions affecting urine acidity (pH), heart disease, or uncontrolled hypertension. This medicine contains specific colorants, so those sensitive to these colorants should be cautious. During treatment, side effects such as dizziness, headaches, constipation, drowsiness, and hypertension may occur; if any unusual symptoms appear, the patient should consult a doctor. Drug interactions may occur when taken with other medications, especially those affecting the central nervous system, and co-administration should either be avoided or dosing should be adjusted accordingly. Women who are pregnant or may become pregnant should make a careful decision about the use of this medicine as it may affect the fetus, and breastfeeding should be stopped if nursing. It is advisable not to use in children or adolescents under 18 years of age due to lack of established safety and efficacy. In case of overdose, serious symptoms may appear in the central nervous system and digestive system, and immediate medical attention should be sought for appropriate treatment. Finally, this medicine may affect the patient's reaction speed and concentration, so caution is advised while driving or operating machinery. Lastly, this medicine should be stored out of reach of children, and transferring it to another container should be avoided for safety reasons.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly sealed container to prevent air or moisture ingress, ideally at room temperature between 1 degree and 30 degrees. Storing in this manner will help maintain the efficacy of the medicine.
Orange rectangular film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Tablet · Prescription medication
JongkunDang Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.